Lucentis

ranibizumab

Opinion

On 25 July 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lucentis. The marketing authorisation holder for this medicinal product is Novartis Europharm Limited.

The CHMP adopted an extension to the existing indication as follows:1

"Lucentis is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV)
  • The treatment of visual impairment due to diabetic macular oedema (DME)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

Lucentis is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease."

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1New text in bold

Key facts

Name
Lucentis
Agency product number
EMEA/H/C/000715
International non-proprietary name (INN) or common name
  • ranibizumab
Active substance
  • ranibizumab
Therapeutic area
Wet Macular Degeneration
Macular Edema
Myopia, Degenerative
Diabetes Complications
Date opinion adopted
25/07/2019
Company name
Novartis Europharm Limited
Status
Positive
Application type
Post-authorisation

How useful was this page?

Add your rating